ENDPOINTS

Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids

Plus, news about Trevi Therapeutics: Kelun Biotech’s $250M stock sale: The Sichuan company upsized its PIPE from $200 to $250 million and included investors from around the globe, including sovereign wealth funds and healthcare specialist ...

Jun 6, 2025 - 15:10
 0
Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids
Plus, news about Trevi Therapeutics: Kelun Biotech’s $250M stock sale: The Sichuan company upsized its PIPE from $200 to $250 million and included investors from around the globe, including sovereign wealth funds and healthcare specialist ...
Read More

Tags:

Previous Article

New Measurements for M87's Supermassive Black Hole: Spin and Accretion Rate

Next Article

What Are Healthcare’s Most Pressing Revenue Integrity Issues in the Remote Work ...

Related Posts

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff

Taysha’s pivotal trial plans; Keros to stop work on PAH...

May 29, 2025  0

Ionis details late-stage data for heart drug; Armata’s promising staph infection therapy

Ionis details late-stage data for heart drug; Armata’s ...

May 19, 2025  0

Regeneron makes $80M obesity deal with Hansoh

Regeneron makes $80M obesity deal with Hansoh

Jun 2, 2025  0